Pancreatic ductal adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas. It affects males more often than females and the patients are usually over 50 years of age. Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation. Signs and symptoms include pain, loss of weight, and jaundice. It grows rapidly and is usually detected after it has metastasized to other anatomic sites. The prognosis is usually poor.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pancreatic ductal adenocarcinoma
- Therapeutic area
- Oncology
- pancreatic ductal adenocarcinoma
- ductal adenocarcinoma of pancreas
- ductal adenocarcinoma of the pancreas
- pancreas ductal adenocarcinoma
- pancreas tubular adenocarcinoma
- pancreatic duct adenocarcinoma
- pancreatic ductal adenocarcinoma
- pancreatic ductal carcinoma
- pancreatic tubular adenocarcinoma
- Severity
- Terminal
- Endocrinology
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0005184
- Parent condition
- MONDO:0005606
Related records
Broader conditions (25)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine system disorder
- Epithelial neoplasm
- Exocrine pancreatic carcinoma
- Glandular cell neoplasm
- Human disease
- Malignant exocrine pancreas neoplasm
- Malignant pancreatic neoplasm
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (6)
- Colloid carcinoma of the pancreas
- Mixed ductal-endocrine carcinoma of pancreas
- Pancreatic foamy gland adenocarcinoma
- Pancreatic signet ring cell adenocarcinoma
- Undifferentiated pancreatic carcinoma
- Undifferentiated pancreatic carcinoma with osteoclast-like giant cells
Trials (500)
- "Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
- A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC
- A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
- A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC
- A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
- A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP
- A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
- A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
- A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Drugs in development (103)
- Abemaciclib Phase 2
- Aldoxorubicin Phase 2
- Ascorbic acid Phase 1
- Atezolizumab Phase 2
- Autogene cevumeran Phase 2
- Avelumab Early phase 1
- Axitinib Phase 3
- Azacitidine Phase 1
- Azenosertib Early phase 1
- Balstilimab Phase 2
- Bevacizumab Phase 1
- Birabresib Phase 1
- BMS-813160 Phase 1
- Camrelizumab Phase 1
- Canakinumab Phase 1
- Capecitabine Phase 3
- Certepetide Phase 2
- Cetuximab Phase 1
- Chlorambucil Phase 2
- Ciprofloxacin Phase 1
Other linked drugs (1)
- Sonidegib